CN107405359B - 包含美洛昔康的药物组合物 - Google Patents

包含美洛昔康的药物组合物 Download PDF

Info

Publication number
CN107405359B
CN107405359B CN201680009582.7A CN201680009582A CN107405359B CN 107405359 B CN107405359 B CN 107405359B CN 201680009582 A CN201680009582 A CN 201680009582A CN 107405359 B CN107405359 B CN 107405359B
Authority
CN
China
Prior art keywords
dosage form
meloxicam
cyclodextrin
pain
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680009582.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN107405359A (zh
Inventor
赫里奥特·塔布提奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antecip Bioventures II LLC
Original Assignee
Antecip Bioventures II LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60389519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107405359(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Antecip Bioventures II LLC filed Critical Antecip Bioventures II LLC
Priority to CN202110356434.5A priority Critical patent/CN113144218A/zh
Publication of CN107405359A publication Critical patent/CN107405359A/zh
Application granted granted Critical
Publication of CN107405359B publication Critical patent/CN107405359B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
CN201680009582.7A 2015-11-25 2016-04-11 包含美洛昔康的药物组合物 Active CN107405359B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110356434.5A CN113144218A (zh) 2015-11-25 2016-04-11 包含美洛昔康的药物组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562259993P 2015-11-25 2015-11-25
US62/259,993 2015-11-25
PCT/US2016/026991 WO2016131067A2 (en) 2015-02-10 2016-04-11 Pharmaceutical compositions comprising meloxicam

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110356434.5A Division CN113144218A (zh) 2015-11-25 2016-04-11 包含美洛昔康的药物组合物

Publications (2)

Publication Number Publication Date
CN107405359A CN107405359A (zh) 2017-11-28
CN107405359B true CN107405359B (zh) 2021-04-20

Family

ID=60389519

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680009582.7A Active CN107405359B (zh) 2015-11-25 2016-04-11 包含美洛昔康的药物组合物
CN202110356434.5A Pending CN113144218A (zh) 2015-11-25 2016-04-11 包含美洛昔康的药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110356434.5A Pending CN113144218A (zh) 2015-11-25 2016-04-11 包含美洛昔康的药物组合物

Country Status (23)

Country Link
US (1) US9821075B2 (cg-RX-API-DMAC7.html)
EP (3) EP4008319B1 (cg-RX-API-DMAC7.html)
JP (6) JP6746612B2 (cg-RX-API-DMAC7.html)
KR (9) KR102465027B1 (cg-RX-API-DMAC7.html)
CN (2) CN107405359B (cg-RX-API-DMAC7.html)
AU (4) AU2016218992C1 (cg-RX-API-DMAC7.html)
CA (4) CA3011562C (cg-RX-API-DMAC7.html)
CY (1) CY1125193T1 (cg-RX-API-DMAC7.html)
DK (1) DK3256138T3 (cg-RX-API-DMAC7.html)
ES (1) ES2913288T3 (cg-RX-API-DMAC7.html)
HU (1) HUE058677T2 (cg-RX-API-DMAC7.html)
IL (3) IL316648A (cg-RX-API-DMAC7.html)
LT (1) LT3256138T (cg-RX-API-DMAC7.html)
MX (2) MX380762B (cg-RX-API-DMAC7.html)
MY (1) MY191574A (cg-RX-API-DMAC7.html)
NZ (1) NZ734233A (cg-RX-API-DMAC7.html)
PL (1) PL3256138T3 (cg-RX-API-DMAC7.html)
PT (1) PT3256138T (cg-RX-API-DMAC7.html)
RS (1) RS63260B1 (cg-RX-API-DMAC7.html)
SG (2) SG10202010157VA (cg-RX-API-DMAC7.html)
SI (1) SI3256138T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200194T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016131067A2 (cg-RX-API-DMAC7.html)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10821181B2 (en) 2015-02-10 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729774B1 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780165B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11110173B2 (en) 2015-02-10 2021-09-07 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US11045549B2 (en) 2015-02-10 2021-06-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10517950B1 (en) 2015-02-10 2019-12-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10537642B1 (en) 2015-02-10 2020-01-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10722583B2 (en) 2015-02-10 2020-07-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729773B2 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10653777B2 (en) 2015-02-10 2020-05-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695429B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US12485176B2 (en) 2015-02-10 2025-12-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695430B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11607456B2 (en) 2015-02-10 2023-03-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933137B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933136B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11738085B2 (en) 2015-02-10 2023-08-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013806B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10532101B1 (en) 2015-02-10 2020-01-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11602563B2 (en) 2015-02-10 2023-03-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10702602B2 (en) 2015-02-10 2020-07-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
SG10202010157VA (en) * 2015-02-10 2020-11-27 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam
US10758618B2 (en) 2015-02-10 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512692B2 (en) 2015-02-10 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10799588B2 (en) 2015-02-10 2020-10-13 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780166B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013805B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11806354B2 (en) 2017-01-04 2023-11-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11266657B2 (en) 2017-01-04 2022-03-08 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583144B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11207327B2 (en) 2017-01-04 2021-12-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11801250B2 (en) 2017-01-04 2023-10-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10905693B2 (en) 2017-01-04 2021-02-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821182B2 (en) 2017-06-29 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617755B2 (en) 2017-01-04 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10561664B1 (en) 2017-01-04 2020-02-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433078B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
DK3565550T3 (da) 2017-01-04 2021-01-18 Axsome Therapeutics Inc Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan
US10471014B2 (en) 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10894053B2 (en) 2017-01-04 2021-01-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729697B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433079B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11471465B2 (en) 2017-01-04 2022-10-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583088B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10940153B2 (en) 2017-01-04 2021-03-09 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729696B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
KR102583443B1 (ko) * 2017-05-10 2023-09-26 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학적 조성물
US11219626B2 (en) 2017-06-29 2022-01-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617756B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758617B2 (en) 2017-06-29 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688185B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617791B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688102B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Combination treatment for migraine and other pain
US10512693B2 (en) 2017-06-29 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11759522B2 (en) 2017-06-29 2023-09-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11510927B2 (en) 2017-06-29 2022-11-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10987358B2 (en) 2017-06-29 2021-04-27 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11185550B2 (en) 2017-06-29 2021-11-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10918722B2 (en) 2017-06-29 2021-02-16 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11865117B2 (en) 2017-06-29 2024-01-09 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US12691123B2 (en) 2017-06-29 2026-07-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
WO2019143560A1 (en) * 2018-01-16 2019-07-25 The Regents Of The University Of California Methods for promoting mitochondrial biogenesis in neural cells
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
CR20210061A (es) * 2018-07-03 2021-03-18 Axsome Therapeutics Inc Composiciones farmacéuticas que comprenden meloxicam
JP2021533177A (ja) 2018-08-23 2021-12-02 チョン クン ダン ファーマシューティカル コーポレイション エソメプラゾール及び炭酸水素ナトリウムを含む、優れた溶解特性を備えた薬学的製剤
WO2020069138A1 (en) * 2018-09-28 2020-04-02 Axsome Therapeutics, Inc. Dosage forms comprising active pharmaceutical ingredients
MY198967A (en) * 2019-02-06 2023-10-05 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam
BR112022001287A2 (pt) * 2019-07-26 2022-04-12 Chong Kun Dang Pharmaceutical Corp Composição farmacêutica
US20240058354A1 (en) 2020-04-06 2024-02-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US12128052B2 (en) 2020-05-28 2024-10-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US20250352552A1 (en) * 2020-11-06 2025-11-20 Mylan Laboratories Ltd Pharmaceutical composition comprising meloxicam
US12648912B2 (en) * 2020-11-06 2026-06-09 Mylan Laboratories Limited Pharmaceutical composition comprising meloxicam
CN116437902A (zh) * 2020-11-06 2023-07-14 迈兰实验室有限公司 包含美洛昔康的医药组成物
JP7495340B2 (ja) * 2020-12-16 2024-06-04 株式会社ファンケル カルノシン酸含有固体組成物及びカルノシン酸の溶出促進方法
KR20230125826A (ko) 2020-12-31 2023-08-29 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학 조성물
US12370196B2 (en) 2020-12-31 2025-07-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
CA3217139A1 (en) * 2021-04-27 2022-11-03 Sang-Jin Lee Composition for preventing or treating muscular disease, comprising oxicam-based compound
US12005118B2 (en) 2022-05-19 2024-06-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US12544383B1 (en) 2025-01-30 2026-02-10 Axsome Therapeutics, Inc. Methods of treating migraines with a combination of a meloxicam and a rizatriptan
US12697341B1 (en) 2025-05-07 2026-08-04 Viatris Inc. Methods of using meloxicam for pain treatment and management

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2565941A1 (en) * 2004-05-04 2005-11-10 Equitech Corporation Improved nsaid composition
CN102526058A (zh) * 2010-12-28 2012-07-04 秦引林 一种含氯诺昔康和埃索美拉唑消炎镇痛药物组合物
CN102625658A (zh) * 2009-05-13 2012-08-01 锡德克斯药物公司 包含普拉格雷和环糊精衍生物的药物组合物及其制备和使用方法
WO2014161131A1 (en) * 2013-04-01 2014-10-09 Arissa Pharma PREPARING AMORPHOUS MELOXICAM-β-CYCLODEXTRIN INCLUSION COMPLEX VIA SPRAY DRYING PROCESS

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3343295A (en) 1994-08-12 1996-03-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Imidazopyridine salt
EP0775120B1 (en) 1994-08-13 2003-06-04 Yuhan Corporation Novel pyrimidine derivatives and processes for the preparation thereof
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
KR20010023256A (ko) * 1997-08-27 2001-03-26 헥살 아게 용해도와 생체 이용성이 개선된 신규의 멜록시캄 의약조성물
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
DK1411900T4 (da) * 2001-06-01 2014-01-27 Pozen Inc Farmaceutiske sammensætninger til den koordinerede frigørelse af NSAIDs
WO2005004915A2 (en) * 2003-07-09 2005-01-20 Boehringer Ingelheim International Gmbh Compositions comprising meloxicam
GB0320382D0 (en) * 2003-08-30 2003-10-01 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Pharmaceutical compositions
WO2005027807A1 (en) 2003-09-19 2005-03-31 Drugtech Corporation Pharmaceutical delivery system
EP1718303A4 (en) 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
US9016221B2 (en) 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
EP1965774A2 (en) * 2005-12-30 2008-09-10 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
US20070281927A1 (en) 2006-06-06 2007-12-06 Shanthakumar Tyavanagimatt Anti-inflammatory and analgesic compositions and related methods
WO2008006216A1 (en) 2006-07-14 2008-01-17 Mistral Pharma, Inc. Anti-inflammatory and cytoprotectant chronotherapy
RU2009131454A (ru) * 2007-01-19 2011-02-27 Такеда Фармасьютикалз Норт Америка, Инк. (Us) Способы предупреждения или уменьшения числа обострений подагры с применением ингибиторов ксантиноксидоредуктазы и противовоспалительных средств
CN101686681B (zh) * 2007-04-27 2015-04-01 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
AU2008265595B2 (en) * 2007-06-20 2014-12-04 PureTech LYT 100 Inc. Substituted N-Aryl pyridinones as fibrotic inhibitors
CN101987081B (zh) 2010-07-16 2012-08-08 钟术光 一种控释制剂
HUE045889T2 (hu) * 2010-10-21 2020-01-28 Rtu Pharmaceuticals Llc Használatkész ketorolak készítmények
DE102010052847A1 (de) 2010-11-29 2012-05-31 Temmler Werke Gmbh Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung
SG10202010157VA (en) 2015-02-10 2020-11-27 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2565941A1 (en) * 2004-05-04 2005-11-10 Equitech Corporation Improved nsaid composition
CN102625658A (zh) * 2009-05-13 2012-08-01 锡德克斯药物公司 包含普拉格雷和环糊精衍生物的药物组合物及其制备和使用方法
CN102526058A (zh) * 2010-12-28 2012-07-04 秦引林 一种含氯诺昔康和埃索美拉唑消炎镇痛药物组合物
WO2014161131A1 (en) * 2013-04-01 2014-10-09 Arissa Pharma PREPARING AMORPHOUS MELOXICAM-β-CYCLODEXTRIN INCLUSION COMPLEX VIA SPRAY DRYING PROCESS

Also Published As

Publication number Publication date
KR20170126915A (ko) 2017-11-20
KR102465027B1 (ko) 2022-11-09
EP4008319A1 (en) 2022-06-08
KR20220107313A (ko) 2022-08-02
KR20200117055A (ko) 2020-10-13
PT3256138T (pt) 2022-05-23
PL3256138T3 (pl) 2022-08-01
CA3204396A1 (en) 2016-08-18
HK1243650A1 (zh) 2018-07-20
AU2019203328B2 (en) 2020-05-28
EP4470614A2 (en) 2024-12-04
AU2016218992B2 (en) 2019-02-14
IL281863A (en) 2021-05-31
KR102827626B1 (ko) 2025-06-30
JP2018508570A (ja) 2018-03-29
CA3011562C (en) 2023-08-29
IL281863B1 (en) 2024-12-01
KR102429352B1 (ko) 2022-08-03
KR20210111333A (ko) 2021-09-10
SG10202010157VA (en) 2020-11-27
IL253925A0 (en) 2017-10-31
IL316648A (en) 2024-12-01
AU2020205306A1 (en) 2020-08-06
KR102163404B1 (ko) 2020-10-08
WO2016131067A3 (en) 2016-10-06
JP2019131596A (ja) 2019-08-08
KR20230038592A (ko) 2023-03-20
MX2021003230A (es) 2022-08-18
CA2976272C (en) 2018-09-04
JP6842122B2 (ja) 2021-03-17
AU2016218992A1 (en) 2017-08-17
AU2019203328A1 (en) 2019-05-30
US9821075B2 (en) 2017-11-21
KR20250099425A (ko) 2025-07-01
JP7332202B2 (ja) 2023-08-23
MX380762B (es) 2025-03-12
KR102447080B1 (ko) 2022-09-23
NZ734233A (en) 2018-05-25
JP7721602B2 (ja) 2025-08-12
JP7017275B2 (ja) 2022-02-08
JP6746612B2 (ja) 2020-08-26
EP3256138A2 (en) 2017-12-20
ES2913288T3 (es) 2022-06-01
NZ742220A (en) 2023-07-28
EP3256138B1 (en) 2022-02-23
KR102507663B1 (ko) 2023-03-07
KR20220110869A (ko) 2022-08-09
EP4008319B1 (en) 2024-11-20
SI3256138T1 (sl) 2022-07-29
CN113144218A (zh) 2021-07-23
KR102424013B1 (ko) 2022-07-25
EP4470614A3 (en) 2025-03-05
DK3256138T3 (da) 2022-05-16
KR20230098923A (ko) 2023-07-04
CA2976272A1 (en) 2016-08-18
SMT202200194T1 (it) 2022-07-21
EP3256138A4 (en) 2019-10-02
KR20220153674A (ko) 2022-11-18
AU2022203861B2 (en) 2024-09-19
AU2020205306B2 (en) 2022-03-10
CN107405359A (zh) 2017-11-28
JP2025142338A (ja) 2025-09-30
IL253925B (en) 2021-04-29
US20160228576A1 (en) 2016-08-11
WO2016131067A2 (en) 2016-08-18
CY1125193T1 (el) 2024-12-13
CA3278634A1 (en) 2025-10-30
KR102550497B1 (ko) 2023-07-03
MX2017010304A (es) 2018-06-19
RS63260B1 (sr) 2022-06-30
JP2022040370A (ja) 2022-03-10
AU2022203861A1 (en) 2022-06-23
JP2023133545A (ja) 2023-09-22
AU2016218992C1 (en) 2019-09-26
AU2020205306C1 (en) 2022-10-13
CA3011562A1 (en) 2016-08-18
AU2019203328C1 (en) 2020-08-27
SG11201706123XA (en) 2017-08-30
LT3256138T (lt) 2022-06-10
IL281863B2 (en) 2025-04-01
HUE058677T2 (hu) 2022-09-28
EP4008319C0 (en) 2024-11-20
CA3204396C (en) 2025-09-09
JP2021066749A (ja) 2021-04-30
MY191574A (en) 2022-06-30

Similar Documents

Publication Publication Date Title
CN113144218A (zh) 包含美洛昔康的药物组合物
JP7368020B2 (ja) メロキシカムを含有する固体医薬組成物の使用
US10456471B2 (en) Pharmaceutical compositions comprising meloxicam
HK40054450A (en) Pharmaceutical compositions comprising meloxicam
HK40119078A (en) Pharmaceutical compositions comprising meloxicam
HK40074468A (en) Pharmaceutical compositions comprising meloxicam
HK40074468B (en) Pharmaceutical compositions comprising meloxicam
HK40019897A (en) Pharmaceutical compositions comprising meloxicam

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant